Literature DB >> 25605815

Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma.

Craig Horbinski1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25605815      PMCID： PMC4483106          DOI： 10.1093/neuonc/nou366

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  3 in total

1.  Monoclonal antibody specific for IDH1 R132H mutation.

Authors:  David Capper; Hanswalter Zentgraf; Jörg Balss; Christian Hartmann; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2009-10-02       Impact factor: 17.088

2.  Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.

Authors:  David Capper; Susanne Weissert; Jörg Balss; Antje Habel; Jochen Meyer; Diana Jäger; Ulrike Ackermann; Claudia Tessmer; Andrey Korshunov; Hanswalter Zentgraf; Christian Hartmann; Andreas von Deimling
Journal:  Brain Pathol       Date:  2009-10-27       Impact factor: 6.508

Review 3.  What do we know about IDH1/2 mutations so far, and how do we use it?

Authors:  Craig Horbinski
Journal:  Acta Neuropathol       Date:  2013-03-20       Impact factor: 15.887
  3 in total
  1 in total

1.  Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria.

Authors:  Michela Visani; Giorgia Acquaviva; Gianluca Marucci; Alexandro Paccapelo; Antonella Mura; Enrico Franceschi; Daniela Grifoni; Annalisa Pession; Giovanni Tallini; Alba A Brandes; Dario de Biase
Journal:  J Neurooncol       Date:  2017-07-26       Impact factor: 4.506
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.